DK2044080T3 - Camptothecin-derivater med antitumor-aktivitet - Google Patents
Camptothecin-derivater med antitumor-aktivitet Download PDFInfo
- Publication number
- DK2044080T3 DK2044080T3 DK07786096.3T DK07786096T DK2044080T3 DK 2044080 T3 DK2044080 T3 DK 2044080T3 DK 07786096 T DK07786096 T DK 07786096T DK 2044080 T3 DK2044080 T3 DK 2044080T3
- Authority
- DK
- Denmark
- Prior art keywords
- tumors
- compound
- hydrogen
- mmols
- aminoalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Claims (11)
1. Forbindelser med den almene formel (I):
(i) hvor: R er F; R1 er hydrogen, alkyl, aminoalkyl, hydroxyalkyl, nitril, alkoxyamino, aryloxy-amino, silylalkyl; R2 er hydrogen, hydroxyl, alkoxy, aminoalkyl; R3 er hydrogen, hydroxyl, alkoxy, aminoalkyl; forudsat, at når R1 er hydrogen, er R2 og R3 hydrogen; hvor alkyl-, alkoxy-, aminoalkyl- eller alkoxyminogrupperne kan indeholde 1 til 8 carbonatomer, i en lige eller forgrenet kæde, og aryloxygrupperne kan indeholde 5 til 10 carbonatomer; de farmaceutisk acceptable salte, enantiomerer, diastereomerer deraf og tilsvarende blandinger.
2. Forbindelse med formel (I) ifølge krav 1, som er: a) 5-F-camptothecin.
3. Fremgangsmåde til fremstilling af forbindelser med formel (I) ifølge krav 1, omfattende trinnene vist i det følgende skema, hvor: a) beskyttelse af prækursor-hydroxygrupperne; b) derivatisering ved 5 ved dannelse af en carbanion og reaktion med et elek-trofilt reagens; c) afbeskyttelse af hydroxygrupperne; Skema
hvor R, R1, R2 og R3 har betydningerne beskrevet ovenfor og PG er en OH-beskyttelsesgruppe.
4. Farmaceutisk sammensætning indeholdende en forbindelse med formel (I) ifølge krav 1 sammen med farmaceutisk acceptable bærere og hjælpestoffer.
5. Farmaceutisk sammensætning ifølge krav 4, som foreligger i en form, der er egnet til oral eller parenteral indgivelse.
6. Anvendelse af en forbindelse ifølge krav 1 eller 2 eller en sammensætning ifølge krav 4 eller 5 til fremstilling af et medikament til behandling af tumorer.
7. Anvendelse ifølge krav 6, hvor medikamentet anvendes til behandling af faste tumorer og leukæmier.
8. Anvendelse ifølge krav 6 eller 7, hvor medikamentet anvendes til behandling af tumorer i lungen, æggestokken, brystet, maven, leveren, prostata, sarkomer i blødt væv, øsofagus, pankreas, hoved og hals, glioblastom, kroniske og akutte myelocytiske leukæmier.
9. Forbindelse med den almene formel (I) ifølge krav 1 eller 2 til anvendelse ved behandling af tumorer.
10. Forbindelse til anvendelse ifølge krav 9, hvor tumorerne er faste tumorer eller leukæmier.
11. Forbindelse til anvendelse ifølge krav 9 eller 10, hvor tumorerne er udvalgt fra gruppen bestående af tumorer i lungen, æggestokken, brystet, maven, leveren, prostata, sarkomer i blødt væv, øsofagus, pankreas, hoved og hals, glioblastom, kroniske og akutte myelocytiske leukæmier.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001474A ITMI20061474A1 (it) | 2006-07-26 | 2006-07-26 | Derivati della camptotecina ad attivita antitumorale |
| PCT/EP2007/006294 WO2008012003A1 (en) | 2006-07-26 | 2007-07-16 | Camptothecin derivatives with antitumor activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2044080T3 true DK2044080T3 (da) | 2017-07-17 |
Family
ID=38668855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07786096.3T DK2044080T3 (da) | 2006-07-26 | 2007-07-16 | Camptothecin-derivater med antitumor-aktivitet |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8193210B2 (da) |
| EP (1) | EP2044080B1 (da) |
| JP (1) | JP5313895B2 (da) |
| KR (1) | KR101496374B1 (da) |
| CN (1) | CN101495485B (da) |
| AU (1) | AU2007278509B2 (da) |
| BR (1) | BRPI0714672B8 (da) |
| CA (1) | CA2658902C (da) |
| DK (1) | DK2044080T3 (da) |
| ES (1) | ES2628022T3 (da) |
| HK (1) | HK1135692A1 (da) |
| IL (1) | IL196652A0 (da) |
| IT (1) | ITMI20061474A1 (da) |
| MX (1) | MX2009000828A (da) |
| NO (1) | NO342506B1 (da) |
| PL (1) | PL2044080T3 (da) |
| PT (1) | PT2044080T (da) |
| RU (1) | RU2450007C2 (da) |
| SI (1) | SI2044080T1 (da) |
| WO (1) | WO2008012003A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9379559B2 (en) | 2012-02-03 | 2016-06-28 | International Business Machines Corporation | System and method of charging a vehicle using a dynamic power grid, and system and method of managing power consumption in the vehicle |
| PL235836B1 (pl) * | 2012-10-25 | 2020-11-02 | Inst Chemii Organicznej Polskiej Akademii Nauk | Pochodne kamptotecyny, sposób ich otrzymywania i zastosowanie |
| CN108690036B (zh) * | 2018-05-22 | 2021-05-25 | 北京海步医药科技股份有限公司 | 一种10-二氟甲基喜树碱类化合物及其制备方法和应用 |
| LU102067B1 (en) | 2020-09-17 | 2022-03-18 | Narodowy Inst Lekow | 7-Ethyl-10-hydroxycamptothecin derivatives for use in the treatment of cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5972955A (en) * | 1995-06-06 | 1999-10-26 | Dr. Reddy's Research Foundation | Water soluble C-ring analogues of 20(S)-camptothecin |
| IT1282673B1 (it) * | 1996-02-23 | 1998-03-31 | Ist Naz Stud Cura Dei Tumori | Derivati della camptotecina e loro uso come agenti antitumorali |
-
2006
- 2006-07-26 IT IT001474A patent/ITMI20061474A1/it unknown
-
2007
- 2007-07-16 US US12/373,834 patent/US8193210B2/en active Active
- 2007-07-16 PL PL07786096T patent/PL2044080T3/pl unknown
- 2007-07-16 BR BRPI0714672A patent/BRPI0714672B8/pt not_active IP Right Cessation
- 2007-07-16 PT PT77860963T patent/PT2044080T/pt unknown
- 2007-07-16 SI SI200731933A patent/SI2044080T1/sl unknown
- 2007-07-16 AU AU2007278509A patent/AU2007278509B2/en not_active Ceased
- 2007-07-16 DK DK07786096.3T patent/DK2044080T3/da active
- 2007-07-16 ES ES07786096.3T patent/ES2628022T3/es active Active
- 2007-07-16 CN CN2007800281978A patent/CN101495485B/zh active Active
- 2007-07-16 MX MX2009000828A patent/MX2009000828A/es active IP Right Grant
- 2007-07-16 RU RU2009102241/04A patent/RU2450007C2/ru active
- 2007-07-16 WO PCT/EP2007/006294 patent/WO2008012003A1/en active Application Filing
- 2007-07-16 JP JP2009521140A patent/JP5313895B2/ja not_active Expired - Fee Related
- 2007-07-16 KR KR1020097001596A patent/KR101496374B1/ko active IP Right Grant
- 2007-07-16 CA CA2658902A patent/CA2658902C/en not_active Expired - Fee Related
- 2007-07-16 EP EP07786096.3A patent/EP2044080B1/en active Active
-
2009
- 2009-01-16 NO NO20090252A patent/NO342506B1/no not_active IP Right Cessation
- 2009-01-22 IL IL196652A patent/IL196652A0/en unknown
-
2010
- 2010-01-15 HK HK10100447.7A patent/HK1135692A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007278509A1 (en) | 2008-01-31 |
| JP2010500971A (ja) | 2010-01-14 |
| KR20090032100A (ko) | 2009-03-31 |
| CA2658902C (en) | 2014-09-23 |
| EP2044080B1 (en) | 2017-05-10 |
| RU2009102241A (ru) | 2010-07-27 |
| WO2008012003A1 (en) | 2008-01-31 |
| CA2658902A1 (en) | 2008-01-31 |
| EP2044080A1 (en) | 2009-04-08 |
| BRPI0714672B8 (pt) | 2021-05-25 |
| AU2007278509B2 (en) | 2012-10-04 |
| ES2628022T3 (es) | 2017-08-01 |
| CN101495485B (zh) | 2012-04-11 |
| US8193210B2 (en) | 2012-06-05 |
| US20100010032A1 (en) | 2010-01-14 |
| CN101495485A (zh) | 2009-07-29 |
| SI2044080T1 (sl) | 2017-07-31 |
| NO342506B1 (no) | 2018-06-04 |
| IL196652A0 (en) | 2009-11-18 |
| NO20090252L (no) | 2009-01-16 |
| RU2450007C2 (ru) | 2012-05-10 |
| BRPI0714672A2 (pt) | 2013-03-26 |
| MX2009000828A (es) | 2009-02-03 |
| PL2044080T3 (pl) | 2017-10-31 |
| PT2044080T (pt) | 2017-06-15 |
| KR101496374B1 (ko) | 2015-03-04 |
| HK1135692A1 (en) | 2010-06-11 |
| BRPI0714672B1 (pt) | 2020-10-20 |
| JP5313895B2 (ja) | 2013-10-09 |
| ITMI20061474A1 (it) | 2008-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2044079T3 (da) | Camptothecinderivater med antitumoraktivitet | |
| DK2044080T3 (da) | Camptothecin-derivater med antitumor-aktivitet | |
| CA2659050C (en) | Camptothecin derivatives with antitumor activity |